Triple-nucleoside regimens versus efavirenz [3] (multiple letters)

New England Journal of Medicine

Volumn 351, Issue 7, 2004, Pages 717-719

  De Luca, Andrea ^a   Di Giambenedetto, Simona ^a   Maida, Ivana ^b   Nuñez, Marina ^b   Soriano, Vincent ^b   Gulick, Roy M ^c   Ribaudo, Heather ^d   Kuritzkes, Daniel ^e  

^a CATHOLIC UNIVERSITY   (Italy)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; EFAVIRENZ; VIRUS RNA; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ABACAVIR; LAMIVUDINE; OXAZINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIVER TOXICITY; META ANALYSIS; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD; DRUG COMBINATION; METHODOLOGY; NOTE;

DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; LAMIVUDINE; OXAZINES; RESEARCH DESIGN; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD; ZIDOVUDINE; PATIENT COMPLIANCE;

EID: 3943076567     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200408123510720     Document Type: Letter

References (0)